Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg; leucine, quantity: 0.432 mg - injection, powder for - excipient ingredients: lactose; sorbitol; mannitol; threonine; serine; proline; glycine; alanine; valine; methionine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg - injection, powder for - excipient ingredients: lactose; mannitol; sorbitol; threonine; serine; proline; glycine; alanine; valine; methionine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml - injection, powder for - excipient ingredients: lactose; mannitol; sorbitol; threonine; serine; proline; glycine; alanine; valine; methionine; isoleucine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immuncompromised patients with no history of the disease.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - varicella virus, live attenuated - powder and solvent for solution for injection - varicella virus, live attenuated nlt 10^3.3 pfu - varicella zoster vaccines - varilrix is intended for the active immunization against varicella of the categories of persons listed below, where there is no history of varicella.- healthy subjects, from the age of 12 months.- patients at high risk of severe varicella, such as patients with acute leukemia or a chronic condition, those on immunosuppressive therapy or those for whom an organ transplant is being considered.healthy persons living in close contact with patients with varicella and high-risk patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - varicella vaccine 2000 pfu (not less than); varicella vaccine 2000 pfu (not less than) - powder for injection with diluent - 2000 pfu - active: varicella vaccine 2000 pfu (not less than) excipient: albumin amino acids lactose monohydrate mannitol sorbitol water for injection active: varicella vaccine 2000 pfu (not less than) excipient: amino acids lactose mannitol sorbitol - varilrix is indicated for active immunisation and prophylaxis against varicella in healthy infants (from the age of 9 months), children, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - varicella vaccine - live -

Malta - English - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - varicella virus, oka strain, live, attenuated - powder and solvent for solution for injection - varicella virus oka strain (live, attenuated) 10 pfu/dose - vaccines

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - varicella-zoster virus live attenuated (oka strain) - powder and solvent for solution for injection